General Information of Drug Combination (ID: DCUX4SM)

Drug Combination Name
Prednisolone Idarubicin
Indication
Disease Entry Status REF
Glioblastoma? Investigative [1]
Component Drugs Prednisolone   DMQ8FR2 Idarubicin   DMM0XGL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T98G
Zero Interaction Potency (ZIP) Score: 11.03
Bliss Independence Score: 11.03
Loewe Additivity Score: 13.73
LHighest Single Agent (HSA) Score: 13.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Prednisolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [2]
Acute asthma CA23 Approved [2]
Addison disease 5A74.0 Approved [2]
Allergic rhinitis CA08.0 Approved [2]
Angioedema 4A00.15 Approved [2]
Aspiration pneumonitis N.A. Approved [2]
Autoimmune haemolytic anaemia 3A20 Approved [2]
Blepharoconjunctivitis N.A. Approved [2]
Bursitis N.A. Approved [2]
Cerebral edema 8D60.1 Approved [2]
Chronic graft versus host disease N.A. Approved [2]
Congenital adrenal hyperplasia 5A71.01 Approved [2]
Corneal abrasion NA06.4 Approved [2]
Corneal ulcer 9A76 Approved [2]
Crohn disease DD70 Approved [2]
Dacryocystitis N.A. Approved [2]
Demodex blepharitis 1G07 Approved [2]
Dermatitis herpetiformis EB44 Approved [2]
Diamond-Blackfan anemia N.A. Approved [2]
Disorder of orbital region N.A. Approved [2]
Epicondylitis N.A. Approved [2]
Erythema multiforme N.A. Approved [2]
Exanthem N.A. Approved [2]
Fever MG26 Approved [2]
Granuloma annulare N.A. Approved [2]
Hypersensitivity pneumonitis N.A. Approved [2]
Inflammatory bowel disease DD72 Approved [2]
Ischemia-reperfusion injury DB98.B Approved [2]
Keratitis N.A. Approved [2]
Leukemia N.A. Approved [2]
Lupus nephritis 4A40.0Y Approved [2]
Microscopic polyangiitis N.A. Approved [2]
Miliary tuberculosis N.A. Approved [2]
Mycosis fungoides 2B01 Approved [2]
Myeloproliferative neoplasm 2A20 Approved [2]
Pneumocystis pneumonia CA40.20 Approved [2]
Polymyalgia rheumatica N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Psoriasis EA90 Approved [2]
Psoriatic arthritis FA21 Approved [2]
Rheumatic heart disease N.A. Approved [2]
Rosacea ED90.0 Approved [2]
Sarcoidosis 4B20.5 Approved [2]
Serum sickness N.A. Approved [2]
Severe asthma CA23 Approved [2]
Skin disease EA00-EM0Z Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Sympathetic ophthalmia N.A. Approved [2]
Systemic lupus erythematosus 4A40.0 Approved [2]
Ulcerative colitis DD71 Approved [2]
Multiple sclerosis 8A40 Phase 3 [4]
Acquired thrombocytopenia N.A. Investigative [2]
Asthma CA23 Investigative [2]
Beta-thalassemia major N.A. Investigative [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
Follicular lymphoma 2A80 Investigative [2]
Iridocyclitis N.A. Investigative [2]
Sjogren syndrome 4A43.20 Investigative [2]
Synovitis N.A. Investigative [2]
Uveitis 9A96.Z Investigative [2]
Prednisolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Prednisolone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Prednisolone Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [13]
------------------------------------------------------------------------------------
Prednisolone Interacts with 121 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [14]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [7]
Phospholipid phosphatase 3 (PLPP3) OTSSF7BK PLPP3_HUMAN Decreases Expression [7]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Decreases Expression [7]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [7]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Decreases Expression [7]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Decreases Expression [7]
Gasdermin-E (GSDME) OT1ZWY32 GSDME_HUMAN Decreases Expression [7]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Decreases Expression [7]
CCN family member 5 (CCN5) OTADU8JJ CCN5_HUMAN Increases Expression [7]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Decreases Expression [7]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Decreases Expression [7]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [7]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [7]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Decreases Expression [7]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [7]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [7]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [7]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [7]
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Expression [7]
Neuromedin-B (NMB) OT4NLN6H NMB_HUMAN Decreases Expression [7]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [7]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [7]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [7]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Decreases Expression [7]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [7]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Decreases Expression [7]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Decreases Expression [7]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Decreases Expression [7]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [7]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [7]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Decreases Expression [7]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [7]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [7]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Decreases Expression [7]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [7]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [7]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Decreases Expression [7]
Interferon alpha-inducible protein 27, mitochondrial (IFI27) OTI2XGIT IFI27_HUMAN Decreases Expression [7]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [7]
Prolargin (PRELP) OT9EEBUJ PRELP_HUMAN Increases Expression [7]
Spermine synthase (SMS) OT8JYKNH SPSY_HUMAN Decreases Expression [7]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Expression [7]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Decreases Expression [7]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [7]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2) OTRZH80H TNAP2_HUMAN Decreases Expression [7]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Increases Expression [7]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Decreases Expression [7]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [7]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [7]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Decreases Expression [7]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Increases Expression [7]
Signal transducer and activator of transcription 4 (STAT4) OTAK3VFR STAT4_HUMAN Decreases Expression [7]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Decreases Expression [7]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [7]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Decreases Expression [7]
Interferon-induced protein 44-like (IFI44L) OTXKORJP IF44L_HUMAN Decreases Expression [7]
Olfactomedin-like protein 2B (OLFML2B) OTDNJFR4 OLM2B_HUMAN Increases Expression [7]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [7]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Decreases Expression [7]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6) OT7G9PQE HERC6_HUMAN Decreases Expression [7]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [7]
Interferon-induced protein 44 (IFI44) OTOKSZVA IFI44_HUMAN Decreases Expression [7]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) OTCA9WCM RSAD2_HUMAN Decreases Expression [7]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Decreases Expression [7]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [7]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Decreases Expression [7]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Decreases Expression [7]
Interferon-induced helicase C domain-containing protein 1 (IFIH1) OTZA2AHA IFIH1_HUMAN Decreases Expression [7]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [7]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [7]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2) OTK0PG7R NUA4L_HUMAN Decreases Expression [7]
Large neutral amino acids transporter small subunit 2 (SLC7A8) OT8XXVO8 LAT2_HUMAN Increases Expression [7]
E3 ISG15--protein ligase HERC5 (HERC5) OTZ5PR39 HERC5_HUMAN Decreases Expression [7]
Paired immunoglobulin-like type 2 receptor alpha (PILRA) OTBE0PLF PILRA_HUMAN Decreases Expression [7]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [7]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [15]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [8]
Inactive phospholipase C-like protein 1 (PLCL1) OTJL2C79 PLCL1_HUMAN Increases Expression [8]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [8]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Increases Expression [8]
Kelch-like protein 24 (KLHL24) OTWZSX5C KLH24_HUMAN Increases Expression [8]
Protein FAM200C (FAM200C) OTZOXUEK F200C_HUMAN Increases Expression [8]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [8]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [8]
Cysteine-rich motor neuron 1 protein (CRIM1) OTTZNV6Y CRIM1_HUMAN Increases Expression [8]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [8]
PDZ and LIM domain protein 1 (PDLIM1) OT4EGCPG PDLI1_HUMAN Increases Expression [16]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) OTMI12L2 BMAL1_HUMAN Increases Expression [17]
Period circadian protein homolog 2 (PER2) OTU2B1DJ PER2_HUMAN Decreases Expression [17]
Period circadian protein homolog 1 (PER1) OTVQF3WX PER1_HUMAN Increases Expression [17]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [18]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [19]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [16]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [20]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Increases Expression [20]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [21]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Response To Substance [22]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [23]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [23]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [21]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [16]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [9]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [9]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [9]
Ganglioside GM2 activator (GM2A) OTIRWZC0 SAP3_HUMAN Increases Expression [16]
Nuclear receptor subfamily 1 group D member 1 (NR1D1) OTJ38PTB NR1D1_HUMAN Decreases Expression [17]
C-X-C chemokine receptor type 2 (CXCR2) OTISGW7L CXCR2_HUMAN Decreases Expression [24]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [16]
Growth/differentiation factor 5 (GDF5) OTOV8S81 GDF5_HUMAN Decreases Expression [25]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Decreases Expression [16]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Decreases Expression [16]
D site-binding protein (DBP) OTE0W7LN DBP_HUMAN Decreases Expression [17]
Cryptochrome-1 (CRY1) OTTGAJT0 CRY1_HUMAN Decreases Expression [17]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [26]
Lymphocyte antigen 96 (LY96) OTN4HXA2 LY96_HUMAN Decreases Expression [16]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases ADR [27]
Histone-lysine N-methyltransferase 2A (KMT2A) OT9GLJI6 KMT2A_HUMAN Decreases Response To Substance [28]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Metabolism [29]
Mothers against decapentaplegic homolog 1 (SMAD1) OTQSHR25 SMAD1_HUMAN Increases ADR [27]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases ADR [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 121 DOT(s)
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [5]
Acute myeloid leukaemia 2A60 Approved [6]
Adult acute monocytic leukemia N.A. Approved [5]
Childhood acute megakaryoblastic leukemia N.A. Approved [5]
Leukemia N.A. Approved [5]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [31]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [32]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [33]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [33]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [34]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [34]
------------------------------------------------------------------------------------
Idarubicin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [30]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [35]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Activity [30]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [36]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Activity [30]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [37]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Activity [30]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [38]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Prednisolone FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
5 Idarubicin FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
7 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
8 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
9 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
10 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
11 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
12 Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
13 Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
14 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
15 CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
16 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
17 Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
18 Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 2001 Dec;38(6):1191-8. doi: 10.1053/ajkd.2001.29209.
19 Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009 May;11(5):463-71. doi: 10.1093/eurjhf/hfp028. Epub 2009 Feb 20.
20 Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
21 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
22 Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006 Mar;65(3):301-5. doi: 10.1136/ard.2005.040816. Epub 2005 Aug 3.
23 JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclo-hexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model. J Pharmacol Exp Ther. 2005 Jul;314(1):293-301. doi: 10.1124/jpet.104.080846. Epub 2005 Apr 8.
24 CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease. Curr Eye Res. 2005 Mar;30(3):195-203. doi: 10.1080/02713680490904331.
25 Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. Scand J Rheumatol. 2008 Nov-Dec;37(6):401-9. doi: 10.1080/03009740802120010.
26 Dermatomyositis associated with membranous nephropathy in a 43-year-old female. Am J Nephrol. 2002 Jul-Aug;22(4):385-8. doi: 10.1159/000065233.
27 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
28 In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004 Mar;18(3):521-9. doi: 10.1038/sj.leu.2403253.
29 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
30 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
33 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
34 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
35 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
36 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
37 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
38 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.